• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

迷走神经刺激治疗难治性癫痫的成本效益

Cost-benefit of vagus nerve stimulation for refractory epilepsy.

作者信息

Boon P, Vonck K, D'Have M, O'Connor S, Vandekerckhove T, De Reuck J

机构信息

Department of Neurology, University Hospital, Gent, Belgium.

出版信息

Acta Neurol Belg. 1999 Dec;99(4):275-80.

PMID:10674145
Abstract

PURPOSE

Vagus nerve stimulation (VNS) is an established treatment for patients with medically refractory epilepsy who are unsuitable candidates for conventional epilepsy surgery. VNS requires an initial financial investment but apart from our own previous study there are no reports on cost-benefit published to date. The purpose of this paper is to assess prospectively the cost-benefit ratio of VNS in a series of patients with long term follow-up.

METHODS

Our experience with VNS comprises 25 patients of whom 20 with sufficient follow-up will be further discussed. These 20 patients have a mean post-implantation follow-up of 26 months (range: 6-50 months). Mean age was 30 years (range: 12-45 years); mean duration of epilepsy 17 years (range: 5-35 years). We prospectively assessed seizure frequency, prescribed AEDs, number of hospital admission days and side effects and calculated the epilepsy related direct medical cost and compared this with pre-implantation data.

RESULTS

Mean seizure frequency decreased from 14 seizures/month (range: 2-40) to 9 seizures/month (range: 0-30) (p = 0.0003). The mean yearly epilepsy related direct medical costs per patient dropped from 6,682 USD (range: 829-21,888 USD) to 3,635 USD (range: 684-12,486 USD) (p = 0.0046). The mean number of hospital admission days was reduced from 16 days/year (range: 0-60) to 4 days/year (range: 0-30) (p = 0.0029).

CONCLUSION

VNS is an efficacious and cost-beneficial treatment for refractory partial seizures.

摘要

目的

迷走神经刺激术(VNS)是一种针对药物治疗难治性癫痫且不适合传统癫痫手术的患者的既定治疗方法。VNS需要初始资金投入,但除了我们之前的研究外,迄今尚无关于成本效益的报道。本文旨在对一系列长期随访患者的VNS成本效益比进行前瞻性评估。

方法

我们对VNS的经验包括25例患者,其中20例有足够的随访资料将进一步讨论。这20例患者植入后的平均随访时间为26个月(范围:6 - 50个月)。平均年龄为30岁(范围:12 - 45岁);癫痫平均病程为17年(范围:5 - 35年)。我们前瞻性评估了癫痫发作频率、处方抗癫痫药物、住院天数和副作用,并计算了癫痫相关的直接医疗费用,并将其与植入前的数据进行比较。

结果

平均癫痫发作频率从每月14次发作(范围:2 - 40次)降至每月9次发作(范围:0 - 30次)(p = 0.0003)。每位患者每年癫痫相关的直接医疗费用从6682美元(范围:829 - 21888美元)降至3635美元(范围:684 - 12486美元)(p = 0.0046)。平均住院天数从每年16天(范围:0 - 60天)降至每年4天(范围:0 - 30天)(p = 0.0029)。

结论

VNS是治疗难治性部分性癫痫的一种有效且具有成本效益的治疗方法。

相似文献

1
Cost-benefit of vagus nerve stimulation for refractory epilepsy.迷走神经刺激治疗难治性癫痫的成本效益
Acta Neurol Belg. 1999 Dec;99(4):275-80.
2
Vagus nerve stimulation for refractory epilepsy: a Belgian multicenter study.迷走神经刺激治疗难治性癫痫:一项比利时多中心研究。
Eur J Paediatr Neurol. 2007 Sep;11(5):261-9. doi: 10.1016/j.ejpn.2007.01.008. Epub 2007 Mar 28.
3
[Long-term efficiency of vagus nerve stimulation (VNS) in non-surgical refractory epilepsies in adolescents and adults].[迷走神经刺激术(VNS)对青少年及成人非手术难治性癫痫的长期疗效]
Rev Neurol (Paris). 2007 Dec;163(12):1169-77. doi: 10.1016/S0035-3787(07)78401-1.
4
Refractory epilepsy in tuberous sclerosis: vagus nerve stimulation with or without subsequent resective surgery.结节性硬化症的耐药性癫痫:迷走神经刺激术联合或不联合后续切除术。
Epilepsy Behav. 2009 Nov;16(3):454-60. doi: 10.1016/j.yebeh.2009.08.018. Epub 2009 Sep 19.
5
Vagus nerve stimulation for refractory epilepsy: long term efficacy and side-effects.迷走神经刺激治疗难治性癫痫:长期疗效和副作用
Chin Med J (Engl). 2004 Jan;117(1):58-61.
6
Vagus nerve stimulation for medically refractory epilepsy; efficacy and cost-benefit analysis.迷走神经刺激治疗药物难治性癫痫:疗效及成本效益分析
Acta Neurochir (Wien). 1999;141(5):447-52; discussion 453. doi: 10.1007/s007010050324.
7
Vagus nerve stimulation in pediatric patients with intractable epilepsy: case series and operative technique.
Am Surg. 2001 Feb;67(2):119-21.
8
VNS Therapy versus the latest antiepileptic drug.迷走神经刺激疗法与最新抗癫痫药物的对比
Epileptic Disord. 2005 Sep;7 Suppl 1:S22-6.
9
Long-term outcome of vagus nerve stimulation therapy in patients with refractory epilepsy.迷走神经刺激疗法对难治性癫痫患者的长期疗效。
J Clin Neurosci. 2008 Feb;15(2):127-9. doi: 10.1016/j.jocn.2007.07.083.
10
Cardiac autonomic control in patients with refractory epilepsy before and during vagus nerve stimulation treatment: a one-year follow-up study.难治性癫痫患者在迷走神经刺激治疗前及治疗期间的心脏自主神经控制:一项为期一年的随访研究。
Epilepsia. 2006 Mar;47(3):556-62. doi: 10.1111/j.1528-1167.2006.00467.x.

引用本文的文献

1
Vagus nerve stimulation: a physical therapy with promising potential for central nervous system disorders.迷走神经刺激:一种对中枢神经系统疾病具有潜在前景的物理治疗方法。
Front Neurol. 2024 Dec 13;15:1516242. doi: 10.3389/fneur.2024.1516242. eCollection 2024.
2
Treatment of Drug-Resistant Epilepsy With Right-Sided Vagus Nerve Stimulation.右侧迷走神经刺激治疗耐药性癫痫
Cureus. 2024 Jul 21;16(7):e65061. doi: 10.7759/cureus.65061. eCollection 2024 Jul.
3
Complications and Mortality Rate of Vagus Nerve Stimulation for Drug-Resistant Epilepsy.
迷走神经刺激术治疗耐药性癫痫的并发症及死亡率
Cureus. 2024 Jul 4;16(7):e63842. doi: 10.7759/cureus.63842. eCollection 2024 Jul.
4
Surgical complications of vagus nerve stimulation surgery: A 14-years single-center experience.迷走神经刺激术的手术并发症:一项为期14年的单中心经验。
Brain Spine. 2023 Dec 14;4:102733. doi: 10.1016/j.bas.2023.102733. eCollection 2024.
5
Health Technology Assessment Report on Vagus Nerve Stimulation in Drug-Resistant Epilepsy.《迷走神经刺激治疗耐药性癫痫的卫生技术评估报告》
Int J Environ Res Public Health. 2020 Aug 24;17(17):6150. doi: 10.3390/ijerph17176150.
6
Corpus callosotomy versus vagus nerve stimulation for atonic seizures and drop attacks: A systematic review.胼胝体切开术与迷走神经刺激术治疗失张力发作和跌倒发作的系统评价
Epilepsy Behav. 2015 Oct;51:13-7. doi: 10.1016/j.yebeh.2015.06.001. Epub 2015 Aug 3.
7
Safe Treatment of Seizures in the Setting of HIV/AIDS.HIV/AIDS 环境中的癫痫发作的安全治疗。
Curr Treat Options Neurol. 2013 Aug;15(4):529-43. doi: 10.1007/s11940-013-0237-6.
8
Stimulation of the nervous system for the management of seizures: current and future developments.
CNS Drugs. 2003;17(2):101-15. doi: 10.2165/00023210-200317020-00003.